New hope for mysterious cancers: immune drug trial shows promise
NCT ID NCT05024968
Summary
This study tested an immunotherapy drug called sintilimab for patients with advanced cancer of unknown primary origin (CUP), a rare and difficult-to-treat cancer where the original site is unknown. The trial enrolled 10 patients whose cancer had progressed after standard chemotherapy. The goal was to see if the drug could help control the cancer and was safe for this specific group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF UNKNOWN PRIMARY SITE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.